COMPANY
Reelin Therapeutics, Inc.
Funding and NIH signals
- NIH award NIH awarded $241K (STTR Phase I 5R41AG094356-02, continuation, notice Aug 14, 2026). NIH RePORTER 5R41AG094356-02 (Aug 14, 2026)
Evidence (1 event)
- Aug 14, 2026 · NIH RePORTER 5R41AG094356-02
Organization: REELIN THERAPEUTICS, INC.; City/State: SAN DIEGO, CA; Project number: 5R41AG094356-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 241313; Administering IC: National Institute on Aging; Project title: Identification of next generation gamma-secretase modulators for Alzheimer's disease; Organization type: Domestic For-Profits
- Aug 14, 2026 · NIH RePORTER 5R41AG094356-02